New effective treatment for inflammat... - Lung Conditions C...

Lung Conditions Community Forum

55,524 members66,262 posts

New effective treatment for inflammatory diseases found.

2greys profile image
8 Replies

New research conducted by the University of Liverpool and AKL Research and Development Ltd (AKLRD), published in Inflammopharmacology, highlights the potential benefits of a new drug treatment on the human body’s immune response in inflammation.

In a number of inflammatory conditions, such as osteoarthritis, rheumatoid arthritis and, more recently, COVID-19, major complications and extensive tissue damage can occur when the immune system becomes excessively and uncontrollably activated. Finding new ways to selectively control this over-activity could have major clinical benefits.

news.liverpool.ac.uk/2020/0...

Written by
2greys profile image
2greys
To view profiles and participate in discussions please or .
Read more about...
8 Replies
HungryHufflepuff profile image
HungryHufflepuff

This sounds promising. Hopefully it will be.

Redrum46 profile image
Redrum46

You are very good with your reports makes me feel we have hope xx

pete45 profile image
pete45

Tried to access the links but said the page had moved. Very interested in anything to calm down inflammation.

micox profile image
micox

link doesn't work!

HungryHufflepuff profile image
HungryHufflepuff in reply to micox

It worked yesterday 🤔 I have the page saved on my phone (which doesn't help you at all, sorry!)

HungryHufflepuff profile image
HungryHufflepuff in reply to micox

New research conducted by the University of Liverpool and AKL Research and Development Ltd (AKLRD), published in Inflammopharmacology, highlights the potential benefits of a new drug treatment on the human body’s immune response in inflammation.

In a number of inflammatory conditions, such as osteoarthritis, rheumatoid arthritis and, more recently, COVID-19, major complications and extensive tissue damage can occur when the immune system becomes excessively and uncontrollably activated. Finding new ways to selectively control this over-activity could have major clinical benefits.

Neutrophils

To be healthy, we need an effective immune response, otherwise we would succumb to overwhelming infection, even by everyday bacteria. However, sometimes our immune system can become hyperactive and cause damage through inflammation, even in the absence of any infection. This can sometimes be extreme. Indeed, many rheumatic diseases such as rheumatoid arthritis and osteoarthritis are caused by inflammation. The quest has always been to find ways to selectively block the harmful effects of an overactive immune system, without paying the price of blocking our ability to fight infections.

Neutrophils are the most abundant immune cells in our blood. They are rapidly dispatched to sites of infection, where they fulfil their life-saving antimicrobial functions by destroying infectious organisms and producing signalling proteins called cytokines, that help co-ordinate the recruitment and activity of other immune system cells to the battle against the infection. There is much evidence from work in Liverpool to show that these cells are important players behind many rheumatic diseases

Cytokine storms and COVID-19

In some situations, if the levels of cytokines are too high, they can trigger an extreme inflammatory reaction called a cytokine storm. These storms cause overwhelming inflammation that leads to blocked or ruptured blood vessels. This can affect the entire circulatory system. Cytokine storms can cause immense damage, multiple organ failure, sepsis, and even death and, appear to play a major role in severe COVID-19 disease.

For many decades scientists and clinicians have understood the potential benefit of suppressing neutrophils, but any attempt to do this without weakening the immune response to infection has failed.

APPA

APPA* is a novel drug under development by AKLRD for use in osteoarthritis, a major disabling problem world-wide that is caused by low grade inflammation. The first part of its formal clinical evaluation in Liverpool, led by rheumatologist Professor Robert Moots, has recently been successfully completed. Now, in partnership between Liverpool and AKLRD, the impact of the drug on neutrophils has been examined and published.

The study found that APPA clearly demonstrated anti-inflammatory potential but without weakening host defence to infection.

Robert Moots, Professor of Rheumatology at the University of Liverpool and Director for Research and Development at Aintree University Hospital, said: “We have shown that APPA has the potential to dampen down that bad inflammation that causes rheumatic diseases – but not impact on the crucial antimicrobial function of neutrophils. We have been waiting for too many years for such a selective drug”.

“Our results suggest a prime role for APPA in helping safely modify aggressive immune response, not only in the arthritis that I treat every day, but even, potentially, in COVID-19.”

Professor Steve Edwards, a neutrophil scientist on the project at University of Liverpool said: “Therapeutically targeting the harmful effects of neutrophils in inflammation, without interfering with their ability to fight off infections, has been a long-term goal of many scientists worldwide. At last, we may be able now to realise this goal.”

David Miles, CEO of AKLRD said: “These exciting results underpin the favourable clinical results observed in patients with Osteoarthritis, whilst also suggesting APPA has an important role to play in treating a broad range of conditions where inflammation is involved”.

The full paper, entitled ‘APPA (apocynin and paeonol) modulates pathological aspects of human neutrophil function, without supressing antimicrobial ability, and inhibits TNFα expression and signalling’, can be found here link.springer.com/article/1...

Category

Digital University

Featured Story 1

Press Release

Research

University home page

Tags

Aintree University Hospital NHS Foundation Trust

COVID-19 news

Faculty of Health and Life Sciences

Institute of Integrative Biology

Professor Robert Moots

University retains European Commission HR Excellence in Research Award

New effective treatment for inflammatory diseases found

Virtual events and activities to take part in this week: 1-7 June 2020

Study to provide new insights into social and geographical differences of older population

Social Media

Latest from @livuninews

“An exciting drug with HUGE potential!”

Professor Moots on the potential benefits of a new drug treatment on the body’s immune response in inflammation that could also help #COVID19 patients

#livunitoday #livunicovid #DailyUpdate

@LivHospitals @livuniHLS @aklrd_ltd

1/ Today, we are launching our 11th COVID-19 Policy Brief with @LpoolCityRegion, a paper by Dr Asangaedem Akpan, Ageing Specialty Research Group Lead @NIHRCRN_nwcoast, entitled ‘Care Homes & COVID-19: How we can Prepare for Future Outbreaks’

#LivUniCOVID #LCRPolicyMatters

New @livunigeog research project, supported by @NuffieldFound, to better understand variations in characteristics, behaviours and needs of older people in England bit.ly/3coESgb

facebook Facebook

Twitter Twitter

youtube Youtube

instagram Instagram

Press Release Archive

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

University of Liverpool, Liverpool L69 3BX, United Kingdom

+44 (0)151 794 2000

© University of Liverpool – a member of the Russell Group / Terms and Conditions / Map / Contact us

facebook Twitter youtube instagram linkedin

2greys profile image
2greys in reply to HungryHufflepuff

Thanks HH, that saves me hours of searching through my browser cache. That link at the end is still available:

bit.ly/3coESgb

HungryHufflepuff profile image
HungryHufflepuff in reply to 2greys

You're welcome, thanks for posting the article in the first place, I was very glad to share it again.

You may also like...

Found this

rbht.nhs.uk/first-uk-patients-get-pioneering-new-treatment-for-serious-lung-disease Could be...

Autoimmune arthritis vs bronchiectasis treatments.

who have bronchiectasis and came up with a new treatment for me to consider. She wants me off the...

Lung Cancer Treatment

know cancer treatments are improving every day and also wondered if there is anything else new?

My latest treatment for colonised Pseudomonas

won't necessarily need Iv antibiotics yet .. The new very young consultant I saw is trying me on...

Interstitial Lung disease...caused by rheumatoid arthritis

connective tissue disease subsets, or the lung disease subsets that all seem so connected. I'm new...